Home › FDA Approves Mercks GRASTEK (Timothy Grass Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Grass Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Children and Adults
 

Keywords :   


FDA Approves Mercks GRASTEK (Timothy Grass Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Grass Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Children and Adults

2014-04-14 23:59:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. GRASTEK is the Only FDA Approved Sublingual Allergy Immunotherapy Tablet Indicated for Children as Young as 5 Years of Age WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved GRASTEK (Timothy Grass Pollen Allergen Extract) Tablet for Sublingual Use [2800 Bioequivalent Allergy Units (BAU)]. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: without children treat adults

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
10.05How crops are being disaster-proofed
10.05'I got married on a Thursday and saved 3,000'
10.05Inland Packaging receives Molson Coors Packaging Supplier of the Year
10.05Delays warning as M25 stretch closes for the weekend
10.05AAPI-Owned Three Ships Beauty Raises $2.5 Million
10.05Post Office boss denies covering tracks
10.05Three BASF Women in Manufacturing Honored at the 2024 Women MAKE Awards
10.05BASF Invests in Expansion of Additives Plant in Nanjing
More »